​
​

Xenetic Biosciences (XBIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

XBIO Stock Forecast

Xenetic Biosciences stock forecast is as follows:

Xenetic Biosciences Financial Forecast

Xenetic Biosciences Revenue Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
Revenue-----$611.17K$651.00K$605.84K$486.97K$414.25K$416.71K$388.99K$332.60K$349.27K$287.60K$191.22K$151.33K$115.93K$112.93K$56.75K
Avg Forecast$230.00K$750.00K$540.00K$510.00K$670.00K$460.00K$440.00K$610.00K$490.00K$410.00K$420.00K$390.00K$100.00K$200.00K$290.00K$60.00K$129.50K$127.00K$60.00K$110.51K
High Forecast$230.00K$750.00K$540.00K$510.00K$670.00K$460.00K$440.00K$610.00K$490.00K$410.00K$420.00K$390.00K$100.00K$200.00K$290.00K$60.00K$129.50K$127.00K$60.00K$132.61K
Low Forecast$230.00K$750.00K$540.00K$510.00K$670.00K$460.00K$440.00K$610.00K$490.00K$410.00K$420.00K$390.00K$100.00K$200.00K$290.00K$60.00K$129.50K$127.00K$60.00K$88.41K
# Analysts111111111111711713137714
Surprise %-----1.33%1.48%0.99%0.99%1.01%0.99%1.00%3.33%1.75%0.99%3.19%1.17%0.91%1.88%0.51%

Xenetic Biosciences's average Quarter revenue forecast for Dec 23 based on 1 analysts is $670.00K, with a low forecast of $670.00K, and a high forecast of $670.00K. XBIO's average Quarter revenue forecast represents a 9.63% increase compared to the company's last Quarter revenue of $611.17K (Sep 23).

Xenetic Biosciences EBITDA Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts111111111111711713137714
EBITDA-----$-1.15M$-1.20M$-915.17K$-1.56M$-839.83K$-2.68M$-1.61M$-1.86M$-1.37M$-1.12M$-1.36M$-1.21M$7.99M$-975.35K$-1.22M
Avg Forecast$-230.00K$-750.00K$-540.00K$-510.00K$-670.00K$-460.00K$-440.00K$-610.00K$-490.00K$-246.00K$-252.00K$-1.01M$-60.00K$-120.00K$-174.00K$-1.13M$-77.70K$-76.20K$-36.00K$-1.57M
High Forecast$-230.00K$-750.00K$-540.00K$-510.00K$-670.00K$-460.00K$-440.00K$-610.00K$-490.00K$-246.00K$-252.00K$-811.29K$-60.00K$-120.00K$-174.00K$-905.41K$-77.70K$-76.20K$-36.00K$-1.25M
Low Forecast$-230.00K$-750.00K$-540.00K$-510.00K$-670.00K$-460.00K$-440.00K$-610.00K$-490.00K$-246.00K$-252.00K$-1.22M$-60.00K$-120.00K$-174.00K$-1.36M$-77.70K$-76.20K$-36.00K$-1.88M
Surprise %-----2.49%2.72%1.50%3.19%3.41%10.62%1.59%31.08%11.39%6.43%1.20%15.60%-104.83%27.09%0.78%

13 analysts predict XBIO's average Quarter EBITDA for Dec 20 to be $-77.70K, with a high of $-77.70K and a low of $-77.70K. This is -100.97% lower than Xenetic Biosciences's previous annual EBITDA (Sep 20) of $7.99M.

Xenetic Biosciences Net Income Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts111111111111711713137714
Net Income-----$-1.06M$-1.05M$-797.93K$-1.38M$-760.25K$-2.64M$-1.54M$-1.81M$-1.33M$-1.09M$-1.32M$-1.20M$-7.56M$-924.83K$-1.13M
Avg Forecast$-308.34K$-215.84K$-1.28M$-1.20M$-1.17M$-1.73M$-1.74M$-863.36K$-1.54M$-924.48K$-2.93M$-1.01M$-2.31M$-1.85M$-2.00M$-1.14M$-3.08M$-10.25M$-3.39M$-1.58M
High Forecast$-308.34K$-215.84K$-1.28M$-1.20M$-1.17M$-1.73M$-1.74M$-863.36K$-1.54M$-924.48K$-2.93M$-811.29K$-2.31M$-1.85M$-2.00M$-911.10K$-3.08M$-10.25M$-3.39M$-1.26M
Low Forecast$-308.34K$-215.84K$-1.28M$-1.20M$-1.17M$-1.73M$-1.74M$-863.36K$-1.54M$-924.48K$-2.93M$-1.22M$-2.31M$-1.85M$-2.00M$-1.37M$-3.08M$-10.25M$-3.39M$-1.89M
Surprise %-----0.61%0.60%0.92%0.90%0.82%0.90%1.52%0.78%0.72%0.54%1.16%0.39%0.74%0.27%0.71%

Xenetic Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. XBIO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Xenetic Biosciences SG&A Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts111111111111711713137714
SG&A-----$737.24K$945.95K$925.74K$857.17K$863.23K$1.03M$907.31K$977.58K$945.12K$890.70K$930.58K$880.56K$804.15K$787.49K$927.88K
Avg Forecast$13.42M$43.77M$31.51M$29.76M$39.10M$26.84M$25.68M$35.60M$28.59M$23.93M$24.51M$22.76M$5.84M$11.67M$16.92M$3.50M$7.56M$7.41M$3.50M$6.45M
High Forecast$13.42M$43.77M$31.51M$29.76M$39.10M$26.84M$25.68M$35.60M$28.59M$23.93M$24.51M$22.76M$5.84M$11.67M$16.92M$3.50M$7.56M$7.41M$3.50M$7.74M
Low Forecast$13.42M$43.77M$31.51M$29.76M$39.10M$26.84M$25.68M$35.60M$28.59M$23.93M$24.51M$22.76M$5.84M$11.67M$16.92M$3.50M$7.56M$7.41M$3.50M$5.16M
Surprise %-----0.03%0.04%0.03%0.03%0.04%0.04%0.04%0.17%0.08%0.05%0.27%0.12%0.11%0.22%0.14%

Xenetic Biosciences's average Quarter SG&A projection for Dec 23 is $39.10M, based on 1 Wall Street analysts, with a range of $39.10M to $39.10M. The forecast indicates a 5203.32% rise compared to XBIO last annual SG&A of $737.24K (Sep 23).

Xenetic Biosciences EPS Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
# Analysts111111111111711713137714
EPS-----$-0.69$-0.69$-0.53$-0.10$-0.05$-0.19$-0.11$-0.18$-0.13$-0.12$-0.15$-0.14$-1.20$-0.15$-0.18
Avg Forecast$-0.20$-0.14$-0.83$-0.78$-0.76$-1.12$-1.13$-0.56$-1.00$-0.60$-1.90$-1.20$-1.50$-1.20$-1.30$-1.30$-2.00$-6.65$-2.20$-3.70
High Forecast$-0.20$-0.14$-0.83$-0.78$-0.76$-1.12$-1.13$-0.56$-1.00$-0.60$-1.90$-1.20$-1.50$-1.20$-1.30$-1.30$-2.00$-6.65$-2.20$-3.70
Low Forecast$-0.20$-0.14$-0.83$-0.78$-0.76$-1.12$-1.13$-0.56$-1.00$-0.60$-1.90$-1.20$-1.50$-1.20$-1.30$-1.30$-2.00$-6.65$-2.20$-3.70
Surprise %-----0.62%0.61%0.95%0.10%0.09%0.10%0.09%0.12%0.11%0.09%0.12%0.07%0.18%0.07%0.05%

According to undefined Wall Street analysts, Xenetic Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to XBIO previous annual EPS of $NaN (undefined).

Xenetic Biosciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
IMMXImmix Biopharma$1.69$7.00314.20%Buy
ZURAZura Bio$3.21$10.00211.53%Buy
GOVXGeoVax Labs$3.03$8.00164.03%Buy
XBIOXenetic Biosciences$3.94$4.001.52%-
PALIPalisade Bio$2.39$1.50-37.24%Buy

XBIO Forecast FAQ

What are Xenetic Biosciences's analysts' financial forecasts?

XBIO's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.03M (high $2.03M, low $2.03M), average EBITDA is $-2.03M (high $-2.03M, low $-2.03M), average net income is $-3.006M (high $-3.006M, low $-3.006M), average SG&A $118.46M (high $118.46M, low $118.46M), and average EPS is $-1.95 (high $-1.95, low $-1.95).

Did the XBIO's actual financial results beat the analysts' financial forecasts?

Based on Xenetic Biosciences's last annual report (Dec 2023), the company's revenue was $2.54M, beating the average analysts forecast of $2.18M by 16.51%. Apple's EBITDA was $-4.516M, beating the average prediction of $-2.18M by 107.14%. The company's net income was $-4.135M, missing the average estimation of $-5.504M by -24.88%. Apple's SG&A was $3.56M, missing the average forecast of $127.22M by -97.20%. Lastly, the company's EPS was $-2.71, missing the average prediction of $-3.57 by -24.09%. In terms of the last quarterly report (Sep 2023), Xenetic Biosciences's revenue was $611.17K, beating the average analysts' forecast of $460K by 32.86%. The company's EBITDA was $-1.147M, beating the average prediction of $-460K by 149.28%. Xenetic Biosciences's net income was $-1.056M, missing the average estimation of $-1.727M by -38.87%. The company's SG&A was $737.24K, missing the average forecast of $26.84M by -97.25%. Lastly, the company's EPS was $-0.69, missing the average prediction of $-1.12 by -38.39%